IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Industrial Biotech

Fine Chemicals: Biologics Bounce Back

12:27 PM MST | January 21, 2008 | Deepti Ramesh with Alex Scott

It has been a long time coming, but contract manufacturers are finally beginning to reap financial rewards from their investment in large-molecule therapeutic drugs, also known as biologics or biopharmaceuticals. There have been casualties along the way, however, mainly due to the failure of drugs under development to reach the market. Casualties include Cambrex, which one year ago sold its biologics activities to Lonza, and DSM, which also in the past year was forced to shutter a large-scale biologics manufacturing plant at Montreal and subsequently sell the...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa